Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

6th Annual Drug Development Congress - New Hot Topics Announced

publication date: May 21, 2014
 | 
author/source: Oxford Global

6th annual congress

Oxford Global are pleased to announce the return of the Pharma R&D Europe Series, the leading pharmaceutical discussion forum in Europe.

The series is made up of the following events:

  • 15th Annual Drug Discovery Summit
  • 6th Annual Drug Development Congress
  • 2nd Annual Discovery Chemistry & Drug Design Congress

The first round of topics have now been confirmed for the 6th Annual Drug Development Congress, taking place on the 2nd & 3rd June 2014 in Geneva, Switzerland.

Topics include:

Clinical Predictive Safety: Translational Safety and Safety Biomarkers (Including Imaging)

    • Modelling and simulation for predictive clinical safety – challenges and benefits

    • Examples of clinical safety modelling and simulation for decision-making in drug development

    • Clinical safety biomarkers – key principles, development and qualification for clinical use

    • Examples of clinical safety biomarkers in drug development incl applications of imaging

             CONFIRMED SPEAKER: Magnus Nord, Global Section Director Safety Science, AstraZeneca

Exploratory Toxicology And Mechanism Based Toxicity Testing

  • Incorporation of exploratory toxicology and pathology practices (e.g. target expression profiling, GEM phenotyping, integrated pharmacology, and safety biomarkers) in drug discovery & development

  • Rationale, approach, and balancing resources for achieving success in investigative toxicology studies

  • Proper integration of transcriptomics, biomarkers, and tissue morphology to understand mechanism based toxicity

             CONFIRMED SPEAKER: Vito Sasseville, Executive Director, Preclinical Safety: Discovery & Investigative Safety, NovartisCurrent Trends In Early Development

  • Study design focusing on Adaptive Trials

  • Establishing the Therapeutic Index

  • Incorporating personalized ‘omics’ into early development

  • Gender/ethnobridging in early drug development

             CONFIRMED SPEAKER: Pamela Garzone, Executive Director Biotechnology Clinical Research, Pfizer 

Our speaker programmes have been carefully researched, ensuring delegates are exposed to the highest level of expertise. Confirmed speakers so far include:
  • Pamela Garzone, Executive Director Biotechnology Clinical Research, Pfizer
  • Joerg Bluemel, Director Biologics Safety Assessment, Translational Sciences, MedImmune
  • Magnus Nord, Global Section Director Safety Science, AstraZeneca
  • Vito Sasseville, Executive Director, Preclinical Safety: Discovery & Investigative Safety, Novartis 

 


more about oxford global

 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners